SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-008337
Filing Date
2024-05-16
Accepted
2024-05-15 20:16:50
Documents
17
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrxp-20240514x8k.htm   iXBRL 8-K 46120
2 EX-99.1 nrxp-20240514xex99d1.htm EX-99.1 51145
3 GRAPHIC nrxp-20240514xex99d1001.jpg GRAPHIC 2302
4 GRAPHIC nrxp-20240514xex99d1004.jpg GRAPHIC 159391
  Complete submission text file 0001558370-24-008337.txt   494691

Data Files

Seq Description Document Type Size
5 EX-101.SCH nrxp-20240514.xsd EX-101.SCH 4491
6 EX-101.DEF nrxp-20240514_def.xml EX-101.DEF 14198
7 EX-101.LAB nrxp-20240514_lab.xml EX-101.LAB 20672
8 EX-101.PRE nrxp-20240514_pre.xml EX-101.PRE 15412
20 EXTRACTED XBRL INSTANCE DOCUMENT nrxp-20240514x8k_htm.xml XML 7256
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 24953270
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)